USO 25021
C4551002: ESTUDIO INTERVENCIONISTA, ABIERTO, ALEATORIZADO, MULTICENTRICO, DE FASE III, DE PF-07248144 MÁS FULVESTRANT EN COMPARACIÓN CON EL TRATAMIENTO ELEGIDO POR EL INVESTIGADOR EN PARTICIPANTES ADULTOS CON CÁNCER DE MAMA AVANZADO/METASTÁSICO HER2 NEGATIVO, HER2 NEGATIVO, CUYA ENFERMEDAD HA PROGRESADO DESPUÉS DE UN TRATAMIENTO PREVIO BASADO EN INHIBIDORES DE CDK4/6.
Tipos de enfermedades: Investigación sobre el cáncer de mama
Requisitos de elegibilidad:
• HR+ /HER2-negative (IHC 0/1+, IHC 2+ & ISH-) LA/met BC
• Must have had prior CDK4/6i + ET (adv/met setting) OR adjuvant CDK4/6i + ET
with documented PD/recurrence <12 months after last dose of CDK4/6i
• Must have had 1 prior systemic tx:
• ET monotherapy in adv/met OR
• Rechallenge tx with CDK4/6i + ET adv/met OR
• Targeted therapy for ESR1 or BRCA1/2
• Prior fulvestrant/exemestane is allowed but not required
• Prior chemo, including ADCs, in adv/met setting are excluded
• >2 prior lines of systemic tx in adv/met setting are excluded
• Measurable disease or bone only disease by RECIST v1.1
• Tissue alterations in PIK3CA/AKT1/PTEN (local F1CDx assay) are excluded
• Prior target tx for 1 or more of these alterations are excluded
• FFPE tumor tissue must be provided
• Known active uncontrolled or symptomatic CNS
metastases, carcinomatous meningitis or
leptomeningeal disease excluded
Para más información sobre este juicio , HAGA CLIC AQUÍ.
Disponible en: